The FDA has approved an expanded indication for the gammaCore device to include prevention of migraine.
Researchers assessed the effect of isradipine on clinical progression in previously untreated patients with early-stage PD.
Researchers explored the incidence, clinical characteristics, associated factors, and clinical outcomes of late cerebrovascular events >30- days after TAVR.
The FDA has accepted for Priority Review the supplemental New Drug Application for Epidiolex.
The study compared improvements in frontal lobe dysfunction induced by rTMS and improvement of white matter integrity revealed by diffusion tensor imaging in patients with TRD receiving rTMS treatment.
Researchers developed and validated a clinical and genetic score to identify individuals at high risk for atrial fibrillation and stroke.
Predictors of all-cause hospitalizations in patients with MS included increased age, presence of a comorbidity, and having a history of hospital admissions.
Biohaven announced positive topline results from a pivotal phase 2/3 study evaluating rimegepant for the preventive treatment of episodic and chronic migraine in adults.
Physiologic traits that cause obstructive sleep apnea are also associated with adherence to continuous positive airway pressure in patients with stroke.
Rate of cognitive decline was even faster among widowed participants with higher β-amyloid levels at baseline.